Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
Not a traditional drug phase: Clinical Information System (CIS) / Connect Care Implementation for Diabete Mellitus
This is a retrospective, watch-and-measure (no experimental treatment required) study using routinely collected information collected by Alberta Health Services. The study will identify patients with chronic disease, defined by one or more of the following conditions; diabetes mellitus, heart failure, coronary artery disease, chronic kidney disease, or chronic lung disease.
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 124,240 people at Calgary. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Evaluating the Impact of Alberta Health Services' New Provincial Clinical Information System on Patient Outcomes and Experiences With Chronic Diseases - Study Protocol for a Multi-center Interrupted Time Series Analysis
Interventions: Clinical Information System (CIS) / Connect Care Implementation
Primary outcome (registry wording): All-cause unplanned hospital readmission or death within 30 days after hospital discharge
Who it is for (from inclusion criteria)
Ages 18 Years to any
Adults aged 18 years or older at the time of hospital admission
Residents of Alberta eligible to receive acute-care services in AHS facilities
Hospitalized for any cause during the study period (5 years pre-implementation and 2 years post-implementation of the CIS)
Have a qualifying date for the NCD(s) that occurs prior to or during the index hospital admission
Eligible for inclusion in the primary and patient experience outcomes if they survive to hospital discharge
May enter multiple sub-cohorts if more than one NCD is present
Who the registry excludes
Individuals younger than 18 years at the time of hospital admission
Non-residents of Alberta or individuals not eligible for care within AHS facilities
Hospitalizations that end in death (excluded from analyses of the primary outcome and patient experience measures)
Patients without evidence of any of the five key NCDs during the lookback period or at the index hospital admission
Admissions outside the study period or admissions for which necessary administrative, laboratory, or pharmacy data are unavailable
Kidney diseases related to the immune system include, nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with connective tissue disorders. This study will allow researchers to admit and follow patients suffering from autoimmune diseases of the kidney.
The purpose of the study is to create a Nephrology Tissue Biobank enabling the study of kidney disease from the perspectives of epidemiology, genetics and molecular biology.
This study is aimed to investigate the global transcriptome in order to determine the expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro noncoding-RNAs (miRNAs) in heart failure (HF) and in aortic stenosis (AS). The aim is to clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07609381?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07609381?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.